Skip to main content

Advertisement

Log in

Impact of Lymph Node Ratio on Survival in Papillary Thyroid Cancer

Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

In papillary thyroid cancer, the role of lymph node dissection remains controversial, and staging systems consider metastatic lymph nodes as a binary entity. The purpose of this study was to determine a threshold lymph node ratio (LNR) that impacted disease-specific mortality (DSM).

Methods

We utilized the surveillance, epidemiology, and end results (SEER) database to analyze adult patients who underwent thyroidectomy with lymph node dissection. A LNR (metastatic lymph nodes to total lymph nodes) was calculated after eliminating patients with less than three nodes collected. Kaplan–Meier estimates for DSM were plotted for LNRs and compared by the log rank test. The Cox proportional hazards model was used to evaluate LNR with other known clinical and pathologic determinants of prognosis.

Results

A total of 10,955 cases contained data on lymph nodes. Median follow-up time was 25 months (range 0–59 months), and the mean LNR was 0.28 ± 0.37. After comparing Kaplan–Meier survival estimates and overall DSM rates, we found that a LNR ≥0.42 best divided those with lymph node metastasis based on DSM (p < 0.01). Those with a LNR ≥0.42 experienced a DSM rate of 1.72 % while those with a LNR <0.42 had a DSM rate of 0.65 % (p < 0.01). In addition, patients with a LNR ≥0.42 experienced a 77 % higher DSM rate compared to those with metastatic lymph nodes as a whole. When considered with other known determinants of prognosis, we found that LNR was strongly associated with DSM (hazard ratio 4.33, 95 % confidence interval 1.68–11.18, p < 0.01).

Conclusions

LNR is a strong determinant of DSM, and a threshold LNR of 0.42 can be used to risk-stratify patients with metastatic lymph nodes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–2167.

    Article  PubMed  CAS  Google Scholar 

  2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer database report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer. 1998;83:2638–2648.

    Article  PubMed  CAS  Google Scholar 

  3. Grubbs EG, Evans DB. Role of lymph node dissection in primary surgery for thyroid cancer. J Natl Compr Canc Netw. 2007;5:623–630.

    PubMed  Google Scholar 

  4. Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid: developing pattern of metastasis. Cancer. 1970;26:1053–1060.

    Google Scholar 

  5. Qubain SW, Nakano S, Baba M, Takao S, Aikou T. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery. 2002;131:249–256.

    Article  PubMed  Google Scholar 

  6. Arturi F, Russo D, Giuffrida D, Ippolito A, Perrotti N, Vigneri R, et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol. 1997;82:1638–1641.

    Article  CAS  Google Scholar 

  7. Wada N, Suganuma N, Nakayama H, Masudo K, Rino Y, Masuda M, et al. Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes. Langenbecks Arch Surg. 2007;392:417–422.

    Article  PubMed  Google Scholar 

  8. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine. 1977;56:171–196.

    Article  PubMed  CAS  Google Scholar 

  9. Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005;71:731–734.

    PubMed  Google Scholar 

  10. Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144:1070–1078.

    Article  PubMed  Google Scholar 

  11. Hughes DT, Doherty GM. Central neck dissection for papillary thyroid cancer. Cancer Control. 2011;18:83–88.

    PubMed  Google Scholar 

  12. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery. 2010;148:1100–1106.

    Google Scholar 

  13. Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19:683–689.

    Article  PubMed  Google Scholar 

  14. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–953.

    PubMed  CAS  Google Scholar 

  15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging atlas. New York: Springer; 2010.

  16. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088–1095.

    PubMed  CAS  Google Scholar 

  17. Byar DP, Green SB, Dor P, Williams D, Colon J, van Gilse H, et al. A prognostic index for thyroid carcinoma: a study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033–1041.

    PubMed  CAS  Google Scholar 

  18. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos T, Cooper DS, et al. Prospective multicenter study of thyroid carcinoma treatment. Cancer. 1988;83:1012–1021.

    Google Scholar 

  19. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–428.

    Article  PubMed  CAS  Google Scholar 

  20. Mocellin S, Pasquali S, Rossi CR, Nitti D. Validation of the prognostic value of lymph node ratio in patients with cutaneous melanoma: a population-based study of 8,177 cases. Surgery. 2011;150:83–90.

    Article  PubMed  Google Scholar 

  21. Schiffman SC, McMasters KM, Scoggins CR, Martin RC, Chagpar AB. Lymph node ratio: a proposed refinement of current axillary staging in breast cancer patients. J Am Coll Surg. 2011;213:45–53.

    Article  PubMed  Google Scholar 

  22. Beal SH, Chen SL, Schneider PD, Martinez SR. An evaluation of lymph node yield and lymph node ratio in well-differentiated thyroid carcinoma. Am Surg. 2010;76:28–32.

    PubMed  Google Scholar 

  23. Lang BH, Wong KP, Wan KY, Lo CY. Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection. Ann Surg Oncol. 2012;19:1257–1263.

    Article  PubMed  Google Scholar 

  24. Poehls JL, Chen H, Sippel RS. Preoperative ultrasonography findings predict the need for repeated surgery in papillary thyroid cancer. Endocr Pract. 2012;18:403–409.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

Supported in part by NIH T32 CA00961423.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rebecca S. Sippel MD, FACS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schneider, D.F., Chen, H. & Sippel, R.S. Impact of Lymph Node Ratio on Survival in Papillary Thyroid Cancer. Ann Surg Oncol 20, 1906–1911 (2013). https://doi.org/10.1245/s10434-012-2802-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2802-8

Keywords

Navigation